AgingResearch.NewsJoin free

P16 vivo morpholino

Intervention

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Indiana University Health and 7 more
  • Animals1

Outcomes

3

FOXO signalling

downin human cells1

1 study

  1. P16 vivo morpholino inhibits FOXO signalling in human cells.

    “Biliary E2F1/FOX-O1/IGF-1 signaling increased in human NAFLD/NASH but was blocked by p16 VM.”

    Cellsin human normal, NAFLD, and NASH liver samples/isolated cholangiocytesliver

    p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1/FOXO1/IGF-1 signaling

    Hepatology (Baltimore, Md.)Feb 18, 2023

More on FOXO signalling

Cellular senescence

downin mice1

1 study

  1. P16 vivo morpholino decreases cellular senescence in mice.

    “p16 VM treatment reduced these parameters.”

    Animalsin high fat/high cholesterol diet fed miceliver

    p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1/FOXO1/IGF-1 signaling

    Hepatology (Baltimore, Md.)Feb 18, 2023

More on Cellular senescence

Nonalcoholic fatty liver disease

downin mice1

1 study

  1. P16 vivo morpholino decreases nonalcoholic fatty liver disease in mice.

    “p16 VM treatment reduced these parameters.”

    Animalsin high fat/high cholesterol diet fed miceliver

    p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1/FOXO1/IGF-1 signaling

    Hepatology (Baltimore, Md.)Feb 18, 2023

More on Nonalcoholic fatty liver disease

Latest

Related